These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 24778278

  • 1. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL, Linch SN, Kasiewicz MJ.
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL.
    Proc Natl Acad Sci U S A; 2016 Jan 19; 113(3):E319-27. PubMed ID: 26729864
    [Abstract] [Full Text] [Related]

  • 4. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL, Triplett T, Floyd K, Weinberg AD.
    PLoS One; 2012 Jan 19; 7(4):e34467. PubMed ID: 22496812
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
    Redmond WL, Gough MJ, Weinberg AD.
    Eur J Immunol; 2009 Aug 19; 39(8):2184-94. PubMed ID: 19672905
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.
    Clin Cancer Res; 2017 Oct 15; 23(20):6165-6177. PubMed ID: 28855348
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE, Polesso F, Weinberg AD.
    J Immunol; 2016 Sep 15; 197(6):2509-21. PubMed ID: 27503208
    [Abstract] [Full Text] [Related]

  • 11. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
    Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL.
    J Immunol; 2017 Aug 01; 199(3):974-981. PubMed ID: 28646041
    [Abstract] [Full Text] [Related]

  • 12. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
    Polesso F, Sarker M, Weinberg AD, Murray SE, Moran AE.
    J Immunol; 2019 Oct 01; 203(7):2011-2019. PubMed ID: 31434709
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S.
    PLoS One; 2014 Oct 01; 9(2):e89350. PubMed ID: 24586709
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P.
    J Immunother Cancer; 2019 Apr 11; 7(1):103. PubMed ID: 30975201
    [Abstract] [Full Text] [Related]

  • 20. IL-12 is required for anti-OX40-mediated CD4 T cell survival.
    Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD.
    J Immunol; 2008 Feb 15; 180(4):2140-8. PubMed ID: 18250420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.